Silexion Therapeutics Corp financial data

Symbol
SLXN, SLXNW on Nasdaq
Location
12 Abba Hillel Road, Ramat Gan, Israel
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 129 %
Debt-to-equity -93.3 %
Return On Equity 612 %
Return On Assets -401 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.69M shares
Common Stock, Shares, Outstanding 8.69M shares
Common Stock, Value, Issued 8K USD
Weighted Average Number of Shares Outstanding, Basic 6.78M shares +5968%
Weighted Average Number of Shares Outstanding, Diluted 6.78M shares +5968%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.44M USD -38.6%
General and Administrative Expense 7.53M USD +267%
Operating Income (Loss) -13M USD -32%
Nonoperating Income (Expense) 3.86M USD -49.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -16.8M USD -22.4%
Income Tax Expense (Benefit) 10K USD
Net Income (Loss) Attributable to Parent -16.8M USD -21.9%
Earnings Per Share, Basic 14 USD/shares -97.9%
Earnings Per Share, Diluted 14 USD/shares -97.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.15M USD
Other Assets, Current 58K USD
Assets, Current 7.72M USD
Property, Plant and Equipment, Net 32K USD
Operating Lease, Right-of-Use Asset 502K USD
Assets 8.31M USD +132%
Accounts Payable, Current 722K USD
Employee-related Liabilities, Current 624K USD
Liabilities, Current 2.4M USD
Operating Lease, Liability, Noncurrent 334K USD
Liabilities 5.72M USD
Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value 0 USD -100%
Retained Earnings (Accumulated Deficit) -45M USD
Stockholders' Equity Attributable to Parent 2.59M USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -2.59M USD -261%
Liabilities and Equity 8.31M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.1M USD -40%
Net Cash Provided by (Used in) Financing Activities 7.43M USD
Net Cash Provided by (Used in) Investing Activities -6K USD 0%
Common Stock, Shares Authorized 22.2M shares
Common Stock, Shares, Issued 8.69M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.23M USD +120%
Interest Paid, Excluding Capitalized Interest, Operating Activities 40K USD
Deferred Tax Assets, Valuation Allowance 6.9M USD +25.3%
Deferred Tax Assets, Gross 7.02M USD +26.4%
Operating Lease, Liability 526K USD +208%
Depreciation 21K USD -50%
Payments to Acquire Property, Plant, and Equipment 6K USD 0%
Lessee, Operating Lease, Liability, to be Paid 636K USD
Property, Plant and Equipment, Gross 99K USD -25.6%
Operating Lease, Liability, Current 155K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 167K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 165K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure -7.88%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 110K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 172K USD
Deferred Tax Assets, Operating Loss Carryforwards 5.8M USD +31.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 132K USD
Operating Lease, Payments 56K USD
Additional Paid in Capital 47.6M USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 5.85M USD -34.4%